Table 1 Summary of the patient characteristics and treatments
Variables | No. of patients (%) or Median (range) |
|---|---|
Sex | |
Male | 44 (72.1) |
Female | 17 (27.9) |
Age (years) | 62 (32–92) |
ECOG performance status before radiotherapy | |
< 2 | 19 (31.1) |
≥ 2 | 42 (68.9) |
Disease status before radiotherapy | |
Locally advanced disease | 20 (32.8) |
Combined locally advanced and metastatic disease | 41 (67.2) |
Pathology | |
Tubular adenocarcinoma | 56 (91.8) |
Signet ring cell carcinoma | 5 (8.2) |
Location | |
Proximal | 10 (16.4) |
Body | 25 (41.0) |
Distal | 26 (42.6) |
Baseline hemoglobin level (g/dL) | 7.1 (3.3–10.4) |
Initial symptomsa | |
Melena | 52 (85.2) |
Hematemesis | 20 (32.8) |
Endoscopic hemostasis before radiotherapy | |
Yes | 30 (49.2) |
No | 31 (50.8) |
Angiographic intervention before radiotherapy | |
Yes | 10 (16.4) |
No | 51 (83.6) |
Radiotherapy dose (Gy) | 30 (12.5–50) |
Previous chemotherapy before gastric bleeding | |
Yes | 50 (82.0) |
No | 11 (18.0) |
Additional chemotherapy after radiotherapy | |
Yes | 30 (49.2) |
No | 31 (50.8) |